Analysts Are Bullish on Top Healthcare Stocks: Zymeworks (ZYME), Centessa Pharmaceuticals (CNTA)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Zymeworks (ZYME – Research Report), Centessa Pharmaceuticals (CNTA – Research Report) and Merck & Company (MRK – Research Report) with bullish sentiments.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Zymeworks (ZYME)
Truist Financial analyst Asthika Goonewardene maintained a Buy rating on Zymeworks today. The company’s shares closed last Thursday at $23.63.
According to TipRanks.com, Goonewardene has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Zymeworks has an analyst consensus of Strong Buy, with a price target consensus of $35.55, representing a 44.2% upside. In a report issued on January 12, Bloom Burton also maintained a Buy rating on the stock with a $30.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Centessa Pharmaceuticals (CNTA)
In a report released today, Biren Amin from Piper Sandler maintained a Buy rating on Centessa Pharmaceuticals, with a price target of $38.00. The company’s shares closed last Thursday at $22.40.
According to TipRanks.com, Amin is a 4-star analyst with an average return of
Centessa Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $38.75, representing a 73.7% upside. In a report issued on January 5, Needham also maintained a Buy rating on the stock with a $38.00 price target.
Merck & Company (MRK)
Scotiabank analyst Louise Chen maintained a Buy rating on Merck & Company today and set a price target of $120.00. The company’s shares closed last Thursday at $110.97.
According to TipRanks.com, Chen is a 3-star analyst with an average return of
Merck & Company has an analyst consensus of Moderate Buy, with a price target consensus of $119.80, which is an 8.3% upside from current levels. In a report issued on January 8, Wolfe Research also upgraded the stock to Buy with a $135.00 price target.
